Depo-Provera is considered safe for most people, but it comes with a specific set of trade-offs that matter more for some users than others. It’s a highly effective injectable contraceptive given once every 12 weeks, and its safety profile has been studied extensively over decades. The biggest concerns center on bone density loss, weight gain, a delayed return to fertility, and a possible increase in blood clot risk. None of these are dealbreakers for every user, but they’re worth understanding in detail before you decide.
How Depo-Provera Works
Depo-Provera contains a synthetic form of progesterone that signals your brain to stop triggering ovulation. It suppresses the hormonal surge that normally releases an egg each month, and it does this continuously for about 14 weeks per injection. That’s why the shot is given every 12 weeks: there’s a built-in buffer to keep you protected even if you’re a little late for your next appointment.
The FDA Black Box Warning on Bone Loss
The most prominent safety concern is bone density loss. Depo-Provera carries an FDA black box warning stating that use beyond two years may reduce peak bone mass and increase the risk of osteoporotic fractures later in life. That warning sounds alarming, but the picture is more nuanced than the label suggests.
Users lose about 1.1% of bone density at the hip per year and roughly 0.9% at the spine per year, compared to virtually no loss in non-users. After two years, total bone density loss ranges from about 5.7% to 7.5%. Those numbers are significant, but research from the National Institute of Child Health and Human Development found that bone density largely recovers after stopping the shot. Within about two and a half years of discontinuation, average bone density in former users returned to levels similar to people who never used it.
There’s an important caveat for younger users. In a study of adolescents aged 12 to 18, those who used Depo-Provera for less than two years showed complete bone recovery at all sites. But those who used it for two years or more did not always fully recover bone density at the hip and femoral neck. This is why the two-year guideline matters most for teens and young adults who are still building peak bone mass.
The American College of Obstetricians and Gynecologists takes a more relaxed stance than the black box warning implies. Their guidance acknowledges that bone loss occurs but emphasizes the evidence for recovery after discontinuation. For adult women, ACOG does not treat two years as a hard cutoff, especially when other contraceptive options are unsuitable.
Weight Gain: What the Numbers Show
Weight gain is one of the most common reasons people stop using Depo-Provera, but the average amount is smaller than many expect. In two large clinical trials, users gained less than 2 kilograms (about 3 to 4 pounds) over the first 12 months. The averages were 1.7 kg in the Americas trial and 1.4 kg in the Europe/Asia trial.
That said, averages can be misleading. The standard deviation in those studies was large, meaning some users gained noticeably more while others gained nothing or even lost weight. If you’re someone who notices a significant increase, it’s a real effect for you regardless of what the average shows. Increased appetite appears to be the primary driver rather than a direct metabolic change.
Blood Clot Risk
One study found that Depo-Provera users had a 3.6-fold increased risk of deep vein thrombosis compared to people not using hormonal contraception. That’s a meaningful jump in relative risk, though the absolute risk of blood clots in reproductive-age women is low to begin with (roughly 1 to 5 per 10,000 women per year without hormonal contraception). So a 3.6-fold increase still translates to a small absolute number.
If you have a personal or family history of blood clots, or if you have other risk factors like smoking, obesity, or prolonged immobility, this is worth discussing with your provider before starting the shot.
Cancer Risk
The relationship between Depo-Provera and cancer risk is more reassuring than many people assume. A large study reviewed by ACOG found that injectables like Depo-Provera did not show an increased risk of breast cancer, even though some other hormonal methods did. Methods with higher systemic levels of progestin, which includes injectables, did not appear to be associated with elevated breast cancer risk in that analysis.
Menstrual Changes
Depo-Provera dramatically alters your period, and this is actually a feature for some users and a dealbreaker for others. By 12 months of use, 55% of users report no periods at all. By 24 months, that number rises to 68%. For people with heavy or painful periods, this can be a significant quality-of-life benefit.
In the early months, though, the pattern is often the opposite. Irregular spotting and unpredictable bleeding are common during the first injection cycle or two before the lining of the uterus thins enough to stop bleeding altogether. This early irregularity is not dangerous, but it catches many new users off guard.
Delayed Return to Fertility
If you’re planning to get pregnant in the near future, Depo-Provera’s slow clearance is one of its most important drawbacks. After your last injection, it takes a median of about 6 to 7 months for ovulation to return. The fastest documented return was roughly 3.5 months after the last shot, while the slowest was nearly 12 months.
This delay is not permanent infertility. It’s the drug slowly leaving your system. But it means that if you want to conceive within the next year, Depo-Provera is a poor fit compared to methods like the pill or an IUD, where fertility typically returns within weeks of stopping.
Who It Works Best For
Depo-Provera’s safety profile makes it a strong option for people who want highly effective contraception without daily, weekly, or even monthly maintenance, and who aren’t planning pregnancy in the near term. It’s particularly useful for people who can’t take estrogen-containing methods due to migraine with aura, certain heart conditions, or a history of blood clots with estrogen-based pills (though the shot itself carries some clot risk, the mechanism differs from estrogen-related clotting).
It’s a less ideal choice for adolescents planning to use it for many years, people concerned about weight changes, anyone hoping to conceive soon after stopping, or those with existing low bone density or osteoporosis risk factors. For adults using it beyond two years, the decision involves weighing the bone density trade-off against the benefits, recognizing that current evidence suggests most adults recover that bone after stopping.